The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Cell & gene therapy in pharma: lentiviral vectorsBuy the report here.

Smarter leaders trust GlobalData


Premium Insights Cell & gene therapy in pharma: lentiviral vectors

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Lentiviral vectors is a key innovation area in cell & gene therapy

Lentiviral vectors are a type of viral vector used to deliver genetic material into cells. These vectors are derived from the human immunodeficiency virus (HIV) and can be modified to safely and efficiently deliver therapeutic genes to target cells. Lentiviral vectors are commonly used in gene therapy and are especially useful for targeting cells that are difficult to transfect using other methods.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 690 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of lentiviral vectors.

Key players in lentiviral vectors – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to lentiviral vectors

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
bluebird bio 355 Unlock Company Profile
Centre National de la Recherche Scientifique 251 Unlock Company Profile
Sanofi 233 Unlock Company Profile
Takeda Pharmaceutical 186 Unlock Company Profile
Genethon 184 Unlock Company Profile
Merck 177 Unlock Company Profile
American Gene Technologies International 173 Unlock Company Profile
Oxford BioMedica 171 Unlock Company Profile
Vascular Biogenics 161 Unlock Company Profile
IRCCS Policlinico San Donato 141 Unlock Company Profile
GSK 139 Unlock Company Profile
Eli Lilly 137 Unlock Company Profile
Theravectys 133 Unlock Company Profile
Autolus 132 Unlock Company Profile
Fondazione Telethon 124 Unlock Company Profile
Precigen 123 Unlock Company Profile
Encoded Therapeutics 115 Unlock Company Profile
Tocagen 114 Unlock Company Profile
Sangamo Therapeutics 108 Unlock Company Profile
Selecta Biosciences 104 Unlock Company Profile
Children's Medical Center 103 Unlock Company Profile
Bristol-Myers Squibb 103 Unlock Company Profile
BioMarin Pharmaceutical 94 Unlock Company Profile
PT Soho Global Health 92 Unlock Company Profile
CBMG 90 Unlock Company Profile
Children's Hospital of Philadelphia 89 Unlock Company Profile
Voyager Therapeutics 88 Unlock Company Profile
Johnson & Johnson 88 Unlock Company Profile
Gilead Sciences 87 Unlock Company Profile
Miltenyi Biotec 83 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 83 Unlock Company Profile
RegenxBio 81 Unlock Company Profile
MeiraGTx 78 Unlock Company Profile
Verneuil Participations 78 Unlock Company Profile
Bayer 77 Unlock Company Profile
Regeneron Pharmaceuticals 77 Unlock Company Profile
EXUMA Biotech 76 Unlock Company Profile
Amgen 73 Unlock Company Profile
Biogen 71 Unlock Company Profile
C. H. Boehringer Sohn 69 Unlock Company Profile
Novartis 69 Unlock Company Profile
Esteve Pharmaceuticals 68 Unlock Company Profile
Fred Hutchinson Cancer Research Center 68 Unlock Company Profile
Lonza Group 68 Unlock Company Profile
St. Jude Children’s Research Hospital 67 Unlock Company Profile
2Seventy Bio 66 Unlock Company Profile
Astellas Pharma 66 Unlock Company Profile
WuXi AppTec 64 Unlock Company Profile
Mayo Clinic 64 Unlock Company Profile
Shanghai Unicar-Therapy Bio-Medicine Technology 63 Unlock Company Profile

Source: GlobalData Patent Analytics

bluebird bio is one of the leading patent filers in lentiviral vectors. bluebird bio is a biotechnology company that focuses on the development and commercialization of gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as lentiviral gene addition platform, cancer immunotherapy, and gene editing. Its product pipeline includes elivaldogene autotemcel for the treatment of cerebral adrenoleukodystrophy (CALD), betibeglogene autotemcel for transfusion-dependent beta thalassemia, lovo-cel for the treatment of sickle cell disease, in addition to compounds under development for the treatment of various cancers. Sanofi and Takeda are some of the other key patent filers in lentiviral vectors.

In terms of application diversity, 2Seventy Bio leads the pack, while Amgen and Gilead Sciences stood in the second and third positions, respectively. By means of geographic reach, Selecta Biosciences held the top position, followed by Esteve Pharmaceuticals and C. H. Boehringer Sohn.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.